Last reviewed · How we verify
Dexamethasone-21-Sulfobenzoate, Sodium Salt
Dexamethasone-21-sulfobenzoate is a water-soluble prodrug of the corticosteroid dexamethasone that provides enhanced solubility and bioavailability for systemic anti-inflammatory and immunosuppressive effects.
Dexamethasone-21-sulfobenzoate is a water-soluble prodrug of the corticosteroid dexamethasone that provides enhanced solubility and bioavailability for systemic anti-inflammatory and immunosuppressive effects. Used for Inflammatory and autoimmune disorders requiring systemic corticosteroid therapy, Acute inflammatory conditions.
At a glance
| Generic name | Dexamethasone-21-Sulfobenzoate, Sodium Salt |
|---|---|
| Sponsor | Federal University of São Paulo |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Inflammation |
| Phase | FDA-approved |
Mechanism of action
The sulfobenzoate ester modification improves aqueous solubility compared to dexamethasone base, allowing for better absorption and distribution. Once absorbed, the ester is hydrolyzed to release active dexamethasone, which binds glucocorticoid receptors to suppress inflammatory cytokine production, reduce immune cell activation, and stabilize cell membranes.
Approved indications
- Inflammatory and autoimmune disorders requiring systemic corticosteroid therapy
- Acute inflammatory conditions
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia
- Increased infection risk
- Osteoporosis (with chronic use)
- Mood changes
Key clinical trials
- Laparoscopic Cholecystectomy: General Anesthesia With Opioid Versus General Opioid Free Anesthesia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: